Literature DB >> 2967754

Bioassay for A-56268 (TE-031) and identification of its major metabolite, 14-hydroxy-6-O-methyl erythromycin.

P B Fernandes1, N Ramer, R A Rode, L Freiberg.   

Abstract

A-56268 is a new macrolide which is generally two-fold more potent than erythromycin. A new bioassay is described in which plasma samples are extracted with acetonitrile prior to bioassay. The concentration range for the assay is between 0.05-4.0 micrograms/ml, and the concentrations measured are within 6% of those measured by high-power liquid chromatography. An active metabolite which is as active as erythromycin was identified in the plasma. The plasma half-life and area under the plasma curve values of A-56268, as determined by bioassay, were significantly greater than those of erythromycin.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2967754     DOI: 10.1007/bf01962181

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  1 in total

1.  In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide.

Authors:  P B Fernandes; R Bailer; R Swanson; C W Hanson; E McDonald; N Ramer; D Hardy; N Shipkowitz; R R Bower; E Gade
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

  1 in total
  16 in total

1.  Strength of antimicrobial bone cement decreases with increased poragen fraction.

Authors:  Matt Nugent; Alex McLaren; Brent Vernon; Ryan McLemore
Journal:  Clin Orthop Relat Res       Date:  2010-08       Impact factor: 4.176

2.  Activities of various macrolide antibiotics against Mycobacterium leprae infection in mice.

Authors:  R H Gelber; P Siu; M Tsang; L P Murray
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

3.  Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis.

Authors:  Friederike Traunmüller; Markus Zeitlinger; Petra Zeleny; Markus Müller; Christian Joukhadar
Journal:  Antimicrob Agents Chemother       Date:  2007-07-02       Impact factor: 5.191

4.  Susceptibility of Haemophilus influenzae to clarithromycin alone and in combination with its 14-hydroxy metabolite.

Authors:  A L Barry; P C Fuchs; M A Pfaller
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-12       Impact factor: 3.267

5.  Hand-mixed and premixed antibiotic-loaded bone cement have similar homogeneity.

Authors:  Alex C McLaren; Matt Nugent; Kostas Economopoulos; Himanshu Kaul; Brent L Vernon; Ryan McLemore
Journal:  Clin Orthop Relat Res       Date:  2009-04-24       Impact factor: 4.176

6.  More macrolides.

Authors:  M J Wood
Journal:  BMJ       Date:  1991-09-14

7.  In vitro activity of clarithromycin (TE-031, A-67268) and 14OH-clarithromycin alone and in combination against Legionella species.

Authors:  R N Jones; M E Erwin; M S Barrett
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-11       Impact factor: 3.267

8.  Clarithromycin therapy of experimental Treponema pallidum infections in hamsters.

Authors:  J Alder; K Jarvis; M Mitten; N L Shipkowitz; P Gupta; J Clement
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

9.  Efficacy of clarithromycin for treatment of experimental Lyme disease in vivo.

Authors:  J Alder; M Mitten; K Jarvis; P Gupta; J Clement
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

10.  Efficacies of liposome-encapsulated clarithromycin and ofloxacin against Mycobacterium avium-M. intracellulare complex in human macrophages.

Authors:  C O Onyeji; C H Nightingale; D P Nicolau; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.